ZVRA Zevra Therapeutics Earnings per share increase in current year

Zevra Therapeutics (ZVRA) is protected by exclusive FDA orphan drug rights, creating a formidable market barrier. The annual EPS trend provided by GURU.Markets shows a latest reading of -7.00. This price action is driven by management's transition to a commercial model focused on margins, although cash flow stability remains limited by a narrow patient base and reliance on insurance reimbursements.
Financial and market metric breakdowns for zevra.com (ZVRA)

For Zevra Therapeutics (ZVRA), whose model is based on the commercialization of drugs for rare neurological pathologies, the annual earnings per share (EPS) trend serves as an indicator of the efficiency of the transition to stable cash flow. This metric calculates the percentage shift in net income per share relative to the previous year, allowing investors to compare the asset's market value with the real dynamics of its fundamental profitability.